231 related articles for article (PubMed ID: 11160680)
21. p53 deficiency increases transformation by v-Abl and rescues the ability of a C-terminally truncated v-Abl mutant to induce pre-B lymphoma in vivo.
Zou X; Cong F; Coutts M; Cattoretti G; Goff SP; Calame K
Mol Cell Biol; 2000 Jan; 20(2):628-33. PubMed ID: 10611241
[TBL] [Abstract][Full Text] [Related]
22. In vitro transformation of murine pro-B and pre-B cells by v-mpl, a truncated form of a cytokine receptor.
Fichelson S; Vigon I; Dusanter I; Charon M; Velu T; Baillou C; Gisselbrecht S; Lemoine FM
J Immunol; 1995 Feb; 154(4):1577-86. PubMed ID: 7836743
[TBL] [Abstract][Full Text] [Related]
23. Mutation of Tp53 contributes to the malignant phenotype of Abelson virus-transformed lymphoid cells.
Thome KC; Radfar A; Rosenberg N
J Virol; 1997 Nov; 71(11):8149-56. PubMed ID: 9343165
[TBL] [Abstract][Full Text] [Related]
24. p53 mediates apoptotic crisis in primary Abelson virus-transformed pre-B cells.
Unnikrishnan I; Radfar A; Jenab-Wolcott J; Rosenberg N
Mol Cell Biol; 1999 Jul; 19(7):4825-31. PubMed ID: 10373532
[TBL] [Abstract][Full Text] [Related]
25. Growth, differentiation, and malignant transformation of pre-B cells mediated by inducible activation of v-Abl oncogene.
Jacobsen EA; Ananieva O; Brown ML; Chang Y
J Immunol; 2006 Jun; 176(11):6831-8. PubMed ID: 16709843
[TBL] [Abstract][Full Text] [Related]
26. Insertional mutagenesis of the Abelson murine leukemia virus genome: identification of mutants with altered kinase activity and defective transformation ability.
Rees-Jones RW; Goff SP
J Virol; 1988 Mar; 62(3):978-86. PubMed ID: 2828693
[TBL] [Abstract][Full Text] [Related]
27. Characterization of flat revertants isolated from cells transformed by Abelson murine leukemia virus (Ab-MuLV).
Oka T; Yutsudo M; Inoue H; Higuchi F; Hakura A
J Cell Physiol; 1990 Dec; 145(3):428-33. PubMed ID: 1703165
[TBL] [Abstract][Full Text] [Related]
28. Bcr and Abl interaction: oncogenic activation of c-Abl by sequestering Bcr.
Ling X; Ma G; Sun T; Liu J; Arlinghaus RB
Cancer Res; 2003 Jan; 63(2):298-303. PubMed ID: 12543778
[TBL] [Abstract][Full Text] [Related]
29. v-Abl activates c-myc transcription through the E2F site.
Wong KK; Zou X; Merrell KT; Patel AJ; Marcu KB; Chellappan S; Calame K
Mol Cell Biol; 1995 Dec; 15(12):6535-44. PubMed ID: 8524218
[TBL] [Abstract][Full Text] [Related]
30. The SH2 domain of P210BCR/ABL is not required for the transformation of hematopoietic factor-dependent cells.
Ilaria RL; Van Etten RA
Blood; 1995 Nov; 86(10):3897-904. PubMed ID: 7579359
[TBL] [Abstract][Full Text] [Related]
31. Addition of constitutive c-myc expression to Abelson murine leukemia virus changes the phenotype of the cells transformed by the virus from pre-B-cell lymphomas to plasmacytomas.
Weissinger EM; Mischak H; Goodnight J; Davidson WF; Mushinski JF
Mol Cell Biol; 1993 Apr; 13(4):2578-85. PubMed ID: 8455630
[TBL] [Abstract][Full Text] [Related]
32. p19(Arf) induces p53-dependent apoptosis during abelson virus-mediated pre-B cell transformation.
Radfar A; Unnikrishnan I; Lee HW; DePinho RA; Rosenberg N
Proc Natl Acad Sci U S A; 1998 Oct; 95(22):13194-9. PubMed ID: 9789064
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of Abelson oncogene function by erbstatin analogues.
Kawada M; Tawara J; Tsuji T; Honma Y; Hozumi M; Wang JY; Umezawa K
Drugs Exp Clin Res; 1993; 19(6):235-41. PubMed ID: 8013266
[TBL] [Abstract][Full Text] [Related]
34. Abelson virus transformation prevents TRAIL expression by inhibiting FoxO3a and NF-kappaB.
Wilson MK; McWhirter SM; Amin RH; Huang D; Schlissel MS
Mol Cells; 2010 Apr; 29(4):333-41. PubMed ID: 20213318
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of v-Abl transformation in 3T3 cells overexpressing different forms of the Abelson interactor protein Abi-1.
Ikeguchi A; Yang HY; Gao G; Goff SP
Oncogene; 2001 Aug; 20(36):4926-34. PubMed ID: 11526477
[TBL] [Abstract][Full Text] [Related]
36. bcr/abl and src but not myc and ras replace v-abl in lymphoid transformation.
Engelman A; Rosenberg N
Mol Cell Biol; 1990 Aug; 10(8):4365-9. PubMed ID: 2164639
[TBL] [Abstract][Full Text] [Related]
37. Dok1 and SHIP act as negative regulators of v-Abl-induced pre-B cell transformation, proliferation and Ras/Erk activation.
Oki S; Limnander A; Yao PM; Niki M; Pandolfi PP; Rothman PB
Cell Cycle; 2005 Feb; 4(2):310-4. PubMed ID: 15655368
[TBL] [Abstract][Full Text] [Related]
38. An active v-abl protein tyrosine kinase blocks immunoglobulin light-chain gene rearrangement.
Chen YY; Wang LC; Huang MS; Rosenberg N
Genes Dev; 1994 Mar; 8(6):688-97. PubMed ID: 7926759
[TBL] [Abstract][Full Text] [Related]
39. Point mutations in the abl SH2 domain coordinately impair phosphotyrosine binding in vitro and transforming activity in vivo.
Mayer BJ; Jackson PK; Van Etten RA; Baltimore D
Mol Cell Biol; 1992 Feb; 12(2):609-18. PubMed ID: 1370711
[TBL] [Abstract][Full Text] [Related]
40. Nonrandom cytogenetic changes accompany malignant progression in clonal lines abelson virus-infected lymphocytes.
Clark SS; Liang Y; Reedstrom CK; Wu SQ
Blood; 1994 Dec; 84(12):4301-9. PubMed ID: 7994046
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
